“Studies have shown that psilocybin therapy is effective in relieving emotional and existential distress at the end of life for 65-85% of terminally ill people in clinical trials, when administered properly,” Harris Sliwoski managing partner Vince Sliwoski notes on the firm’s Psychedelics Law Blog. “Many terminal patients cannot swallow….If OHA sticks to this ‘oral only’ stricture in the final rules—based on a restrictive reading of Measure 109 or for any other reason—you can expect some controversy and perhaps even legislative intervention.”
Vincent Sliwoski in Reason
